Literature DB >> 16281510

[A controlled randomized trial of the use of combined L-carnitine and acetyl-L-carnitine treatment in men with oligoasthenozoospermia].

Zheng Li1, Guo-wu Chen, Xue-jun Shang, Wen-jun Bai, Yin-fa Han, Bin Chen, Xiao-ming Teng, Fan-hui Meng, Bin Zhang, De-ning Chen, Ji-hong Liu, Xin-min Zheng, Xiao-rong Cao, Yong Liu, Xiao-bin Zhu, Yi-xin Wang.   

Abstract

OBJECTIVE: To determine the efficacy and safety of combined L-carnitine and acetyl-L-carnitine therapy in infertile males with oligoasthenozoospermia.
METHODS: One hundred fifty patients with oligoasthenozoospermia were randomized selected into treatment and control groups. The treatment group with 90 patients were given L-carnitine (2 g/d) and acetyl-L-carnitine (1 g/d) orally, twice a day. The patients in control group were given Vitamin E 100 mg plus Vitamin C 100 mg, tid. The oral therapy lasted three months and patients accepted sperm analysis every one month. The L-carnitine level in seminal plasma was examined by high performance liquid chromatography (HPC). Side effects as well as pregnant rate were observed.
RESULTS: In the treatment group, 85 patients out of 90 finished the three month treatment. Female spouses of 10 patients (11.6%) achieved pregnancy. Moreover, their forward motile sperm per ejaculation, total motile sperm, as well as the concentration of L-carnitine in seminal plasma were increased significantly (P < 0.01). In control group, 53 patients out of 60 completed three months therapy. Two pregnancy (3.7%) was observed. Though some increase was seen in number of forward motile sperm and total motile sperm per ejaculation, the changes were not statistically significant (P > 0.05). The difference of the pregnant rate between two groups was statistically significant. No side effects were found.
CONCLUSION: Combined treatment with L-carnitine and acetyl-L-calmitine can be an effective and safe option for treating oligoasthenozoospermia by means of significantly improving forward motile sperm and total motile sperm per ejaculation, as well as increasing pregnant rates.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16281510

Source DB:  PubMed          Journal:  Zhonghua Nan Ke Xue        ISSN: 1009-3591


  4 in total

Review 1.  Antioxidants for male subfertility.

Authors:  Wiep de Ligny; Roos M Smits; Rebecca Mackenzie-Proctor; Vanessa Jordan; Kathrin Fleischer; Jan Peter de Bruin; Marian G Showell
Journal:  Cochrane Database Syst Rev       Date:  2022-05-04

2.  Untargeted LC/MS-Based Metabolic Phenotyping of Hypopituitarism in Young Males.

Authors:  Yuwen Zhang; Shouyue Sun; Ming Wang; Wenjuan Yu; Peizhan Chen; Fei Yuan; Xuqian Fang
Journal:  Front Pharmacol       Date:  2021-07-08       Impact factor: 5.810

3.  Antioxidants for male subfertility.

Authors:  Roos M Smits; Rebecca Mackenzie-Proctor; Anusch Yazdani; Marcin T Stankiewicz; Vanessa Jordan; Marian G Showell
Journal:  Cochrane Database Syst Rev       Date:  2019-03-14

4.  Effectiveness comparison of a Chinese dicitraditionalmene formula Wuzi Yanzong Pill and its analogous prescriptions for the treatment of oligoasthenozoospermia: A systematic review and meta-analysis protocol.

Authors:  Yongqiang Li; Yahui Xue; Binghao Bao; Jisheng Wang; Hengheng Dai; Xiaoyong Gong; Wei Zheng; Yanfeng Li; Bao Zhang
Journal:  Medicine (Baltimore)       Date:  2019-05       Impact factor: 1.817

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.